APA (7th ed.) Citation

Mell, L. K., Torres-Saavedra, P. A., Wong, S. J., Kish, J. A., Chang, S. S., Jordan, R. C., . . . Dunlap, N. (2024). Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): An open-label, multicentre, parallel-group, randomised, phase 2/3 trial. Lancet Oncology, 25(12), 1576. https://doi.org/10.1016/S1470-2045(24)00507-2

Chicago Style (17th ed.) Citation

Mell, Loren K., et al. "Radiotherapy with Cetuximab or Durvalumab for Locoregionally Advanced Head and Neck Cancer in Patients with a Contraindication to Cisplatin (NRG-HN004): An Open-label, Multicentre, Parallel-group, Randomised, Phase 2/3 Trial." Lancet Oncology 25, no. 12 (2024): 1576. https://doi.org/10.1016/S1470-2045(24)00507-2.

MLA (9th ed.) Citation

Mell, Loren K., et al. "Radiotherapy with Cetuximab or Durvalumab for Locoregionally Advanced Head and Neck Cancer in Patients with a Contraindication to Cisplatin (NRG-HN004): An Open-label, Multicentre, Parallel-group, Randomised, Phase 2/3 Trial." Lancet Oncology, vol. 25, no. 12, 2024, p. 1576, https://doi.org/10.1016/S1470-2045(24)00507-2.